Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medical Marijuana
  • Medigap Premiums
  • Food Stamp Work Rules
  • Patients in ICE Custody
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Medical Marijuana
  • Medigap Premiums
  • Food Stamp Work Rules
  • Patients in ICE Custody
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Oct 4 2016

Full Issue

House Panel Demands More Information From Mylan In Light Of Tax Omissions

Committee leaders have asked for documents including all of those related to EpiPen sales, profits, costs, manufacturing and distribution of the product; to the CEO's preparation for the committee hearing; documents about Mylan’s tax rates since 2007; and more.

The Wall Street Journal: House Committee Taps Mylan For More Information On EpiPen Price Figures

A U.S. House committee sent a letter to Mylan NV demanding a fuller explanation of why the company omitted key information that it used to calculate the profit figure for the lifesaving EpiPen drug that its chief executive provided during a congressional hearing last month. ... House committee leaders, in a letter to Ms. Bresch dated Sept. 30 and released Monday, said her testimony “omitted key tax assumptions that affect the company’s profit per pack.” They said the omission ”raises questions.” (Loftus, 10/3)

In other pharmaceutical news —

Modern Healthcare: CVS Pushed Out Of Tricare Pharmacy Network

In a blow to CVS Health Corp., pharmacy benefit manager Express Scripts Holding Co. announced it has ousted the provider from the pharmacy network it manages for Tricare, the U.S. Defense Department's health benefits program with 9.4 million beneficiaries. (Livingston, 10/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF